-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Iksuda Therapeutics, editor of WuXi AppTec's content team, announced today that it has completed a financing of US$47 million.
The funds will support the development of its main research antibody conjugate (ADC) and expand its payload and coupling platform technology Development
.
This round of financing was jointly led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners
.
Iksuda's ADC project is aimed at tumors with limited treatment options and high recurrence rates
.
The company's drug development pipeline improves the safety and efficacy of ADCs by combining prodrug payloads that are only activated near the tumor with stable coupling technology
.
Iksuda's research phase pipeline utilizes its proprietary Protein Alkylating (ProAlk) tumor activation payload platform
.
ProAlk's unique mode of action has an adjustable payload, which is different from the current DNA chain or inter-chain cross-linking mechanism, which can help overcome tumor resistance mechanisms and develop more powerful and tolerable ADCs
.
Iksuda's main pre-clinical drug candidate IKS03 is a potential "best-in-class" ADC targeting CD19 for the treatment of B-cell blood cancers
.
This round of financing will enable IKS03 to progress to the human phase 1 clinical trial stage
.
It will also be used to accelerate the company's pre-projects
.
Dr.
Dave Simpson, CEO of Iksuda Therapeutics, said: "This investment allows us to focus on the progress of the ADC project and bring it to the clinic
.
We thank investors for their support and are delighted to welcome them to the team
.
" References: [1] Iksuda Therapeutics closes $47 million financing round.
Retrieved June 7, 2021, from https://iksuda.
com/2021/06/iksuda-therapeutics-closes-47-million-financing-round/ Note: This article aims to introduce The progress of medical and health research is not a treatment recommendation
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
The funds will support the development of its main research antibody conjugate (ADC) and expand its payload and coupling platform technology Development
.
This round of financing was jointly led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners
.
Iksuda's ADC project is aimed at tumors with limited treatment options and high recurrence rates
.
The company's drug development pipeline improves the safety and efficacy of ADCs by combining prodrug payloads that are only activated near the tumor with stable coupling technology
.
Iksuda's research phase pipeline utilizes its proprietary Protein Alkylating (ProAlk) tumor activation payload platform
.
ProAlk's unique mode of action has an adjustable payload, which is different from the current DNA chain or inter-chain cross-linking mechanism, which can help overcome tumor resistance mechanisms and develop more powerful and tolerable ADCs
.
Iksuda's main pre-clinical drug candidate IKS03 is a potential "best-in-class" ADC targeting CD19 for the treatment of B-cell blood cancers
.
This round of financing will enable IKS03 to progress to the human phase 1 clinical trial stage
.
It will also be used to accelerate the company's pre-projects
.
Dr.
Dave Simpson, CEO of Iksuda Therapeutics, said: "This investment allows us to focus on the progress of the ADC project and bring it to the clinic
.
We thank investors for their support and are delighted to welcome them to the team
.
" References: [1] Iksuda Therapeutics closes $47 million financing round.
Retrieved June 7, 2021, from https://iksuda.
com/2021/06/iksuda-therapeutics-closes-47-million-financing-round/ Note: This article aims to introduce The progress of medical and health research is not a treatment recommendation
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
